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Vasopressin in Conjunction With Norepinephrine
in Septic Shock: A Retrospective Cohort Study
From a Low Middle-Income Country
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Hussain Ahmed Raza1; Ainan Arshad, MB BS, FCPS2; Ahmed Ayaz , MB BS1;
Mohummad H. R. Raja1; Fatima Gauhar1; Maria Khan1; Bushra Jamil , MBBS, FRCP, FACP2

Objectives: Guidelines recommend use of norepinephrine as the firstline treatment for fluid-refractory septic shock and if septic shock persists vasopressin may be initiated. Since there are limited data from
low middle-income countries with high disease burden of sepsis, we
aimed to compare the outcomes of using vasopressin adjunct to norepinephrine in comparison with norepinephrine alone.
Design: Retrospective cohort study.
Setting: Aga Khan University Hospital, Karachi, Pakistan.
Patients: Six-hundred fifty-three patients diagnosed with septic shock
from January 2019 to December 2019, with 498 given norepinephrine only and 155 given norepinephrine-vasopressin combination.
Interventions: None.
Measurements and Main Results: Primary outcome was in-hospital
mortality. Secondary outcomes were duration of vasopressor used,
length of hospital stay, length of ICU stay, and days on ventilatory
support. After adjustment by multivariable logistic regression, it was
found that mortality was not significantly associated with the norepinephrine-vasopressin combination (adjusted odds ratio, 0.633 [95%
CI, 0.370–1.081]). However, Sequential Organ Failure Assessment
score at admission (1.100 [1.014–1.193]), lactate at admission
(1.167 [1.109–1.227]), duration of vasopressor used (1.481 [1.316–
1.666]), and level of care (3.025 [1.682–5.441]) were found to be
independently associated with the adjunct usage of norepinephrine
and vasopressin.
Conclusions: The use of norepinephrine-vasopressin combination
has remained debatable in literature. Our study showed that although
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there was no difference in mortality between the two groups, admission Sequential Organ Failure Assessment scores and admission
lactate levels were found to be significantly higher in the norepinephrine-vasopressin group. Hence, physicians from Pakistan used the
norepinephrine-vasopressin combination in resistant septic shock
patients who were sicker to begin with. Furthermore, duration of vasopressor therapy and ICU admission were also significantly higher in
the combination group. Considering the recent hyperinflation of vasopressors costs and that most healthcare expenditure for patients in
Pakistan is out-of-pocket, this can consequently lead to unwarranted
financial burden for patients and their families.
Key Words: mortality; norepinephrine; sepsis; septic shock; shock;
vasopressin

S

epsis, as per the Third International Consensus Definitions
for Sepsis and Septic Shock, is defined as a life-threatening
organ dysfunction caused by a dysregulated host response to
infection (1). Septic shock, a subcategory of sepsis, is when there
are fundamental metabolic, cellular, and circulatory irregularities present which are significant enough to considerably increase
mortality. Millions of people are affected by sepsis and septic
shock every year, causing the death of at least one in four individuals (2, 3). Severe septic shock and sepsis are still critical causes of
mortality and morbidity in present ICUs (4), and despite significant improvement in critical care approach, they are still identified
as the cause of death in 30–50% of hospitalizations (5). Although
data from low middle-income countries (LMICs) have historically
been sparse, outcomes of sepsis have found to be disproportionately affected by location, with Rudd et al recently estimating that
84.8% of sepsis related deaths in 2017 occurred in LMICs (6).
In the event of progression of sepsis to septic shock, where the
patient is unable to maintain a mean arterial pressure (MAP) of
65 mm Hg or greater, despite fluid resuscitation, the use of vasopressors is recommended as per the International Guidelines for
Management of Sepsis and Septic Shock (7). In case norepinephrine fails to raise the MAP adequately, vasopressin may be added to
www.ccejournal.org
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the regimen due to “relative vasopressin deficiency” experienced
within the first 36 hours of onset of septic shock (8, 9). Concomitant
vasopressin administration has been seen to improve vascular
tone, MAP, urine output, and creatinine clearance. Additionally,
vasopressin acts as a catecholamine sparing agent, by effectively
reducing the dosage of norepinephrine required. This may prevent the occurrence of some of the unwanted effects associated
with high-dosage of norepinephrine, including but not limited to
oxidative stress, myocyte injury, and detrimental exacerbation of
sepsis-associated immunoparalysis (10).
In spite of this, the clinically utility of vasopressin in improving outcomes is somewhat unclear, with conflicting data from
prior literature. Two randomized control trials have demonstrated
no significant improvement in mortality following concomitant
norepinephrine and vasopressin administration as compared to
norepinephrine alone (11, 12). Yet, another study demonstrated
increase in mortality when using vasopressin in addition with
norepinephrine that norepinephrine alone (54.4% vs 20.3%;
p < 0.001) (13). Interestingly, within the Vasopressin in Septic
Shock Trial (VASST) trial, it was found that vasopressin administration was beneficial for patients categorized with less severe
septic shock and significantly reduced mortality when compared
with only norepinephrine (26.5% vs 35.7%; p = 0.05) (11). Further
to this, studies have also shown that although concomitant usage
of vasopressin and norepinephrine may not have a mortality benefit, this regimen enables a target MAP of greater than 65 mm Hg
to be reached more quickly (14).
Pakistan has a high disease burden of sepsis, with limited data
and research done in this field. Furthermore, a nationwide registry
of sepsis does not exist. The need for locally sourced data regarding sepsis outcomes, especially from the context of a resource constrained setting of an LMIC, is paramount in allowing physicians
in such areas to make sound evidence-based decisions. Especially
since the clinical utility of adjunct vasopressin therapy continues
to remain controversial and at the discretion of the attending physician. Further to this, the potential benefit of adding vasopressin to the regimen is especially important to elucidate within the
context of an LMIC, since the majority of healthcare financing is
through out-of-pocket expenditure, and as such, adding unnecessary drugs without a clear rationale may lead to undue financial
burden to the patient and their family. Hence, the present study
aims to assess the difference in outcomes between patients receiving norepinephrine and vasopressin, compared with norepinephrine alone, within the setting of an LMIC.

MATERIALS AND METHODS
Study Design and Data Source
This is a retrospective cohort study in which we assessed adult
patients (>18 yr) diagnosed with septic shock from January 2019
till December 2019. This study was conducted at the Aga Khan
University Hospital, which is a Quaternary Care Referral Center with
740 beds located in Karachi city. The Institutional Review Board at
Aga Khan University, Karachi, permitted this study to be conducted.
For the retrospective chart review, two reviewers (authors
F.G., M.K.) independently reviewed patient medical records to
2
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determine their eligibility. Figure 1 shows a flow diagram representing the patient selection process. Records of 1,220 patients
who received vasopressors from January to December 2019
were screened in order to identify those patients who had fluidrefractory septic shock and were administered vasopressin and
norepinephrine. The cases were defined by the International
Classification of Disease, 9th Edition, Clinical Modification
codes for sepsis (995.91), severe sepsis (995.92), or septic shock
(785.52). This method provides a very specific cohort of sepsis;
hence, it is a careful estimate of sepsis patients, as stated by modern literature (15).
A total of 567 studies were excluded by the following exclusion criteria: patients in whom vasopressors/inotropes were used
for reasons other than septic shock; patients who received vasopressors other than norepinephrine and vasopressin, vasopressors used in operation theaters, pregnant mothers, burn injuries;
patients who had a goal MAP of greater than or equal to 70 mm
Hg; postcardiac surgery patients, transferred patients from other
hospitals; and those patients who were discharged from the hospital on request or left against medical advice.
Outcomes
The main outcome we aimed to measure was in-hospital mortality. Secondary outcomes were duration of vasopressor used,
length of hospital stay, length of ICU or special care unit (SCU)
stay, duration of mechanical ventilation, and duration of ventilator free survival (Table 1). Medical ICUs are closed units, whereas
SCUs are open units, both of which follow standardized care for
sepsis management including for fluid therapy and antibiotic
usage, as per sepsis guideline protocols. We also recorded baseline patient characteristics and hospitalization factors including
Sequential Organ Failure Assessment (SOFA) scores and quick
SOFA (qSOFA) scores (Table 2), as well as source of infection and
etiology (Table 3).
Statistical Analysis
Data analysis was done using IBM SPSS Statistics for Windows,
version 23 (IBM Corp., Armonk, NY) and Microsoft Excel 2016
(v16.0). We compared the patient characteristics and clinical
outcomes of the group given norepinephrine only with norepinephrine and vasopressin. We performed this comparison using
the chi-square test and Fisher exact test for categorical variables
and Wilcoxon rank-sum test or Student t test for the continuous
variables. Univariate and multivariable logistic regression were
then performed. Variables with p value less than 0.25 on univariate analysis were included in the multivariable model. Any result
with a p value of less than or equal to 0.05 was considered to be
significant.

RESULTS

In the period between January 2019 and December 2019, there
were 870 patients at the Aga Khan University Hospital who were
diagnosed with septic shock and received vasopressors. After careful assessment of each file, 653 patients met the inclusion criteria
and were studied in detail. Out of these 653 patients, the number
of patients given norepinephrine only was 498 (76.3%), whereas
2020 • Volume 2 • e0274
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Figure 1. Patient selection flow diagram showing the screening process used to obtain records of only those patients diagnosed with septic shock who received
norepinephrine or norepinephrine and vasopressin combination from January to December 2019. MAP = mean arterial pressure.

the number of patients given norepinephrine and vasopressin was
155 (23.7%).
The mean age of the patients was 59.7 ± 16.10, the total number of males was 376 (57.6%), whereas the total number of females
was 277 (42.4%). The most common comorbid conditions were
diabetes (49.0%), hypertension (45.2%), and ischemic heart disease (24.7%). Upon admission, patients who eventually received
TABLE 1.

both norepinephrine and vasopressin had a significantly greater
SOFA score (p = 0.000), qSOFA score (p = 0.005), and serum lactate
(p = 0.000). Furthermore, the level of care between the groups also
significantly varied, with patient requiring adjunct vasopressin
more likely to be admitted to the ICU in comparison with patients
requiring just norepinephrine. The overall demographics, patient
characteristics, and hospitalization factors are presented in Table 2.

Patient Outcomes
Overall
(n = 653)
n (%)/Mean ± sd

Norepinephrine
Only (n = 498)
n (%)/Mean ± sd

Norepinephrine and
Vasopressin (n = 155)
n (%)/Mean ± sd

p

Mortality, n (%)

312 (47.8)

226 (45.4)

86 (55.5)

0.028

Length of hospital stay (d), mean ± sd

8.0 ± 6.20

8.2 ± 6.21

7.4 ± 6.15

0.205

ICU/special care unit length of stay (d), mean ± sd

6.1 ± 4.59

6.2 ± 4.54

5.8 ± 4.76

0.441

Duration on ventilator (d), mean ± sd

5.0 ± 4.08

5.0 ± 3.93

4.8 ± 4.53

0.688

Duration off ventilator (d), mean ± sd

3.0 ± 3.98

3.2 ± 4.18

2.5 ± 3.21

0.071

Duration of vasopressor use (d), mean ± sd

2.4 ± 1.61

2.2 ± 1.44

3.2 ± 1.90

0.000

Outcomes

Boldface values indicate statistically significant (p value ≤0.05) upon analysis.
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TABLE 2.

Patients Characteristics and Hospitalization Factors
Overall
(n = 653)

Norepinephrine
Only (n = 498)

Norepinephrine
and Vasopressin
(n = 155)

p

59.7 ± 16.10

60.9 ± 15.86

55.9 ± 16.33

0.001

Male

376 (57.6)

284 (57.0)

92 (59.4)

0.609

Female

277 (42.4)

214 (43.0)

63 (40.6)

Diabetes

320 (49.0)

247 (49.6)

73 (47.1)

0.586

Hypertension

295 (45.2)

224 (45.0)

71 (45.8)

0.857

Ischemic heart disease

161 (24.7)

125 (25.1)

36 (23.2)

0.636

Chronic kidney disease

153 (23.4)

112 (22.5)

41 (26.5)

0.309

69 (10.6)

51 (10.2)

18 (11.6)

0.628

3.9 ± 2.56

4.0 ± 2.56

3.7 ± 2.56

0.246

SOFA score at admission

5.3 ± 3.35

5.0 ± 3.21

6.3 ± 3.60

0.000

Quick SOFA score at admission

1.5 ± 1.03

1.5 ± 1.04

1.7 ± 0.97

0.005

Lactate at admission (mmol/L)

4.3 ± 3.80

3.7 ± 3.28

6.1 ± 4.69

0.000

Serum creatinine at admission (mg/dL)

3.0 ± 2.86

3.0 ± 3.07

3.0 ± 2.08

0.775

10.7 ± 2.52

10.6 ± 2.41

10.9 ± 2.85

0.350

Patients in ICU care

497 (76.1)

359 (72.1)

138 (89.0)

0.000

Patient in special care unit care

156 (23.9)

139 (27.9)

17 (11.0)

Variables

Mean age (yr), mean ± sd
Gender, n (%)

Comorbid conditions, n (%)

Malignancy
Charlson Comorbidity Index, mean ± sd
Hospitalization factors, mean ± sd

Hemoglobin at admission (g/dL)
Level of care, n (%)

SOFA = Sequential Organ Failure Assessment.
Boldface values indicate statistically significant (p value ≤0.05) upon analysis.

The most common source of infection was unspecified (43.6%)
followed by respiratory tract (24.7%) and urinary (14.5%). The
majority of patients (58.7%) in septic shock did not have any positive site-specific or blood cultures. Additionally, there was a significant difference in the culture reports between the two groups
(p = 0.040). Patients who received norepinephrine alone had a
significantly higher proportion of culture negative reports (60.6%
vs 52.8%), whereas patients who received both vasopressors had a
significantly greater proportion of polymicrobial culture reports
(13.8% vs 8.6%). Detailed microbiological characteristics are presented in Table 3.
The overall mortality for the patients was 312 (47.8%), with significantly increased mortality in the group given both norepinephrine and vasopressin (55.5% vs 45.4%) (p = 0.028). Additionally,
patients given both norepinephrine and vasopressin were on
vasopressor therapy for a longer period of time (3.2 vs 2.2 d) (p =
0.000). Hospital outcomes of both groups are reported in Table 1.
After performing univariate and multivariable logistic regression,
while adjusting for potential confounders, including age, gender,
Charlson Comorbidity Index, and other admission variables,
it revealed that mortality was not significantly associated to the
norepinephrine-vasopressin group (adjusted odds ratio [aOR],
4
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0.633 [95% CI, 0.370–1.081]). However, SOFA score at admission
(aOR, 1.100 [95% CI, 1.014–1.193]), lactate at admission (1.167
[1.109–1.227]), duration of vasopressor use (1.481 [1.316–1.666]),
and level of care (3.025 [1.682–5.441]) were found to be independently associated with the adjunct usage of norepinephrine and
vasopressin. These findings are presented in Table 4.

DISCUSSION

There is a lack of high-quality data on septic shock and vasopressors from LMICs, and to our knowledge, this is the first study in
a resource-constrained setting of an LMIC that has compared the
use of vasopressin in adjunct to norepinephrine versus the use
of norepinephrine alone for the treatment of septic shock. Our
study demonstrated that initially it appeared patients receiving
both norepinephrine and vasopressin had statistically significant
higher rates of mortality than those who received norepinephrine alone. However, once confounding factors were adjusted
for, there was no longer a significant difference between mortality in the two groups, indicating that the mortality in the dual
therapy group was likely due to the higher admission lactate and
admission SOFA scores, rather than the vasopressor combination
itself. This result is largely in line with results from the VASST,
2020 • Volume 2 • e0274
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TABLE 3.

Source of Infection and Etiology
Overall
(n = 653),
n (%)

Norepinephrine
Only (n = 498),
n (%)

Norepinephrine and
Vasopressin (n = 155),
n (%)

p

161 (24.7)

117 (23.5)

44 (28.4)

0.702

Urinary

95 (14.5)

78 (15.7)

17 (11.0)

Central Line Associated
Blood Stream Infection

14 (2.1)

11 (2.2)

3 (1.9)

Cardiac

7 (1.1)

5 (1.0)

2 (1.3)

CNS

9 (1.4)

7 (1.4)

2 (1.3)

Skin/soft tissue

40 (6.1)

32 (6.4)

8 (5.2)

Gastrointestinal

42 (6.4)

29 (5.8)

13 (8.4)

Unspecified

285 (43.6)

219 (44.0)

66 (42.6)

Culture Etiology

Overall
(n = 496)

Norepinephrine
Only (n = 373)

Norepinephrine
and Vasopressin
(n = 123)

p

291 (58.7)

226 (60.6)

65 (52.8)

0.040

  Polymicrobial

49 (9.9)

32 (8.6)

17 (13.8)

  Gram positive

34 (6.9)

22 (5.9)

12 (9.8)

  Gram negative

97 (19.6)

78 (20.9)

19 (15.4)

  Fungi

25 (5.0)

15 (4.0)

10 (8.1)

Characteristics

Source of infection
Respiratory

Culture results
  Culture negative

Boldface value indicates statistically significant (p value ≤0.05) upon analysis.

a multicenter, double-blind, randomized control trial published
in 2008, which reported that the administration of vasopressin at
0.03 U/min 12 hours after the initiation of norepinephrine therapy
did not significantly alter the 28-day and 90-day mortality rates,
when compared with norepinephrine alone (11). The results of
the vasopressin versus norepinephrine as Initial Therapy in Septic
Shock (VANISH) trial conducted in 2016 also stated there was no
difference in mortality between patients given norepinephrine
versus vasopressin (12). In fact, in a recent meta-analysis which
assessed mortality rates in 17 clinical trials which were comparing
vasopressin in combination with catecholamine vasopressors with
catecholamines alone, it was concluded that although mortality
appeared to be lower in the dual therapy group, upon sensitivity
analysis it was no longer significant (16). Yet interestingly, in the
VASST trial, it was noted that vasopressin administration significantly improved 28-day and 90-day survival rates in the subset of
patients with less severe septic shock (patients who were receiving
norepinephrine at an infusion rate of < 15 μg/min) (11). This finding is somewhat contradictory to current guidelines and practices
which suggest that adjunct use of vasopressin, in addition to norepinephrine, is only recommended when the patient is unable to
maintain a MAP above 65 mm Hg with the use of norepinephrine
alone, implying that vasopressin is essentially reserved as a second-line drug to be used in patients with severe septic shock (7).
The results of our study reflect the practice of current guidelines,
Critical Care Explorations

as patients receiving both drugs were clearly sicker from the onset,
as they had significantly higher admission lactate levels and higher
admission SOFA scores, which are well-established prognostic
indicators in septic shock management.
To date, there have been few studies that have shown negative
clinical outcomes associated with the use of vasopressin along with
norepinephrine. In 2007, Micek et al (13) demonstrated increased
28-day mortality with the adjunct use of vasopressin with norepinephrine, in conditions of refractory septic shock (54.4% in
vasopressin group vs. 20.3% in norepinephrine group, p < 0.001),
concluding that the negative effects caused by the mechanism of
action of vasopressin led to the increased mortality. In a propensity matched retrospective cohort study, Russell et al (17) found
that in the same hospital where the VASST trial was conducted, a
similar condition was found in the pre-VASST trial cohort study
conducted at St. Paul’s Hospital (SPH1) (28-d mortality: 60.8% in
vasopressin group vs 46.2% in norepinephrine group; p = 0.009).
However, in the post-VASST trial cohort study conducted at St.
Paul’s Hospital (SPH2), the in-hospital mortality between the two
groups became statistically insignificant (28-d mortality: 31.2% in
vasopressin group vs 26.9% in norepinephrine group; p = 0.518).
A key factor to be noted is that the day 1 dose of vasopressin
administered by physicians between the two periods was significantly different (0.036 U/min (SPH1) vs 0.032 U/min (SPH2); p =
0.001). The decrease in dosage associated with post-VASST period
www.ccejournal.org
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TABLE 4.

Univariate and Multivariable Logistic Regression
Norepinephrine and Vasopressin

Variables

Age

Crude OR (95% CI)

p

Adjusted OR (95% CI)a

p

0.981 (0.971–0.992)

0.001

0.985 (0.971–0.999)

0.043

1.100 (0.763–1.587)

0.609

0.977 (0.890–1.072)

0.618

Gender
Male
Female

Reference

Diabetes

0.905 (0.631–1.298)

0.586

Hypertension

1.034 (0.720–1.485)

0.857

Ischemic heart disease

0.903 (0.591–1.380)

0.636

Chronic kidney disease

1.240 (0.819–1.876)

0.310

Malignancy

1.152 (0.651–2.037)

0.628

Charlson Comorbidity Index

0.958 (0.892–1.030)

0.246

Hemoglobin at admission (g/dL)

1.038 (0.967–1.114)

0.307

Serum creatinine at admission (mg/dL)

0.991 (0.929–1.056)

0.774

SOFA score at admission

1.125 (1.066–1.188)

< 0.001

1.100 (1.014–1.193)

0.022

Quick SOFA score at admission

1.278 (1.070–1.525)

0.007

1.134 (0.868–1.483)

0.357

Lactate at admission (mmol/L)

1.159 (1.108–1.212)

< 0.001

1.167 (1.109–1.227)

< 0.001

Duration on ventilator (s)

0.991 (0.947–1.036)

0.688

Duration of vasopressor use (s)

1.403 (1.259–1.564)

< 0.001

1.481 (1.316–1.666)

< 0.001

3.143 (1.831–5.396)

< 0.001

3.025 (1.682–5.441)

< 0.001

0.028

0.633 (0.370–1.081)

0.094

Level of care
Patients in ICU care
Patients in Special Care Unit care
Mortality

Reference
1.500 (1.044–2.156)

OR = odds ratio, SOFA = Sequential Organ Failure Assessment.
a
Adjusted for variables with p < 0.25 on univariate analysis.
Boldface values indicate statistically significant (p value ≤0.05) upon analysis.

appears to have reduced the mortality in the vasopressin group. In
conjunction with this, literature has reported that higher doses of
vasopressin are associated with several adverse outcomes, including ischemic complications of the heart, gut, and renal systems
(18).
The serum lactate level is a key biomarker to predict mortality and prognostic outcome in patients with septic shock. Current
guidelines suggest initiating and monitoring resuscitation therapy
in such a manner so as to normalize raised lactate levels, with
elevated lactate levels being an indicator of tissue hypoperfusion
(7). Lower lactate levels with greater lactate clearance have consistently been associated with improved outcomes and lower mortality (19–21). In fact, a recent study by Liu et al (22) found lactate to
be an independent predictor for mortality in septic patients. This
has been substantiated by our study’s results, which demonstrated
that higher mortality was not due to the vasopressor combination
itself but rather due to the higher admission lactate level which
was independently associated to the norepinephrine-vasopressin
group. This once again demonstrates that physicians continue to
6
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reserve the use of dual therapy in patients who are significantly
sicker. However, a post hoc analysis of the VASST trial found
that vasopressin administration had a significant mortality benefit for lower serum lactate concentration (< 2 mmol/L) rather
than higher lactate levels above 2 mmol/L (23). These findings
were corroborated by Sacha et al (24) with a reduced lactate levels independently associated with a greater chance of an adequate
hemodynamic response to vasopressin and norepinephrine therapy. To potentially explain this phenomenon, Severson et al (25)
showed that administration of vasopressin was associated with
rising serum lactate levels during therapy. As such adjunct vasopressin therapy may have the potential to elevate the serum lactate levels further despite our findings suggesting that vasopressin
administration in conjunct to norepinephrine was not associated
to increased mortality. These studies demonstrate findings that
are largely in contradiction to the currently accepted practices,
where vasopressin is reserved for substantially sicker patients.
Although both groups in the present study had mean lactate levels
at admission well above the cut off value of 2 mmol/L which was
2020 • Volume 2 • e0274
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used in these previous studies, our results support the notion that
increased lactate levels are associated to vasopressin-norepinephrine usage. The question remains, however as to what lactate level
is appropriate to begin adjunct vasopressin therapy, for which further large-scale studies are needed.
Additionally, in our study, a higher SOFA score at admission
was independently associated to patients in the norepinephrinevasopressin group compared with the norepinephrine group. The
SOFA score, originally designed to predict ICU mortality, measures organ dysfunction in six organ systems and is a key predictor
of mortality in patients with septic shock. Jones et al (26) showed
that SOFA scores can be used to predict mortality with fairly good
accuracy in patients with severe sepsis at the time of presentation
in the emergency department. This was reflected in our study
since the mortality in the combination group was not significant
upon adjustment, indicating that the higher SOFA scores of the
combination group patients caused the patients to be more critical
to begin with. However, a study conducted by Hammond et al (14)
did show a contrasting finding that there was no significant difference in median SOFA scores between norepinephrine alone versus vasopressin and norepinephrine. Nonetheless, SOFA score has
been shown to have strong discriminative power, similar to lactate, for predicting 30-day mortality as shown by a recent study of
sepsis patients (22). This once again reflects in physician attitudes
practicing within an LMIC, suggesting that they are more likely to
start dual therapy in case of higher SOFA scores and continue to
use it along with lactate as an important prognostic indicator in
predicting mortality in septic patients.
Following logistic regression, our study also found that longer
duration of vasopressor therapy and ICU admission were independently associated to the norepinephrine-vasopressin combination group. This is most likely a manifestation of severity of sepsis
and use of combination therapy for sicker patients who were not
responding to norepinephrine alone. Patients in the combination
group were undoubtedly found to be more critical upon admission,
with higher lactate and SOFA scores, leading to their protracted
course of illness and hence needing longer duration of therapy
and more ICU admission. Although appropriate recognition and
management of septic shock is vital to prevent unwarranted mortality, economic restraints and costs for sepsis treatment cannot be
ignored especially in LMICs such as Pakistan. Globally, sepsis is
widely regarded as one of the most expensive conditions to treat.
Although data for LMICs have historically been sparse, it would
be unfair to underestimate that the impact of healthcare costs in
LMICs. Within a high-income country like the United States, the
treatment and subsequent management of sepsis is estimated to
have an annual cost of approximately $20 billion (27). Sepsis treatment costs at a LMIC like Indonesia, varied between $1,011 and
$1,406 per patient, with the national burden estimated to be $130
million per 100,000 sepsis patients (28). This is particularly troubling since Pakistan, which has a similar population to Indonesia,
has an entire healthcare budget of approximately only $150 million for the fiscal year 2020–2021 (29). To add to this financial
crisis, in the recent years, hyperinflation of vasopressor drugs has
drastically occurred, with vasopressin cost in particular increasing
by 60-fold in 2017 than it did in 2015 as shown by a study (30).
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Although healthcare costs in the United States are covered mostly
by medical insurance, in majority of LMICs like Pakistan, very
minimal percentage of the population has access to any form of
health insurance that covers medicine costs. Thus, it is evident
that most healthcare financing in Pakistan is out-of-pocket, with
70% of healthcare costs being covered by this method (31). High
costs severely restrict access to ICU care in LMICs, especially for
the majority of the population in Pakistan who are socioeconomically deprived and uninsured. In fact, many patients in Pakistan
who cannot afford healthcare costs, especially in private hospitals,
often leave the hospital against medical advice. The longer duration of vasopressor treatment and ICU admission, along with the
mammoth out-of-pocket healthcare costs for treatment, will cause
patients and their families in LMICs like Pakistan to experience
significant unwarranted financial burden. This may further limit
access to vital healthcare and treatment in Pakistan and consequently leads to unfortunate outcomes for septic shock patients,
due to the lack of affordability. Therefore, further large-scale studies, particularly in LMICs, are required which advocates for the
clinical benefit of using vasopressin and norepinephrine, so that
both patients and physicians alike are assured that the high costs
for vasopressor treatment are justified.
One of the limitations of this study is that being a retrospective study, the results may have been influenced by unmeasured
residual confounding factors. Furthermore, the present study is
a single-center study, inevitably leading to a smaller sample size
as compared to multicenter studies. In the given study, the SOFA,
qSOFA, and serum lactate levels were recorded upon admission
and were not charted during the hospital admission. To gain a better understanding, further prospective studies are required where
these variables are monitored in conjunction with administration
of vasopressors. Further to this, due to the retrospective nature of
the study, the initiation timings and dosage of vasopressors could
not be accurately determined from our medical records, and
hence these factors were not included in the study. Prior literature
has shown that the timing of the dose of vasopressin may also be
critical in eliciting a positive response. In fact, Lauzier et al (32)
recently demonstrated that vasopressin administration was not
able to raise and maintain the MAP above 70 mm Hg for most
patients, in the early phases of hyperdynamic septic shock. The
VANISH trial also found that higher doses of vasopressin (up to
0.06 U/min), administered within 6 hours of the patient entering
septic shock had no effect on mortality (12). Therefore, further
large-scale studies specifically deducing whether the timing of
vasopressor administration significantly affects outcomes within
an LMIC are warranted. Finally, another limitation lies in identifying septic shock by using MAP. Even though MAP is used
routinely in clinical practice, other clinical variables are also used
for the diagnosis of shock. Furthermore, a MAP of below 65 mm
Hg does not always mean under perfusion of organs and cellular
injury (33). Nevertheless, ICUs continue to use MAP as an indicator of septic shock, and since it is easily accessible, it remains as
an ideal marker for future studies similar to ours. Despite these
limitations, this study presents important results that are of clinical relevance, especially considering that this is the first study of
its kind conducted in a LMIC, which has significantly different
www.ccejournal.org
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socioeconomic demographic conditions. Furthermore, this article
advocates that the vasopressin should be used with caution, especially considering the fact that there is reported potential overuse
of vasopressin among physicians in the United States (34).

CONCLUSIONS

The benefit of the use of Vasopressin in adjunct to Norepinephrine
has remained debatable in scientific literature, with a lack of data
from LMICs. Our study showed that although there was no difference in mortality between the two groups, admission SOFA
scores and admission lactate levels were found to be significantly
higher in the norepinephrine-vasopressin combination group.
Hence, physicians from Pakistan used the combination therapy in resistant septic shock patients who were sicker to begin
with. Furthermore, duration of vasopressor therapy and ICU
admission was also significantly higher in the norepinephrinevasopressin group. Considering the recent hyperinflation of vasopressors costs and that most healthcare expenditure for patients
in Pakistan is out-of-pocket, this can consequently lead to unwarranted financial burden for patients and their families. Therefore,
future studies, especially from LMICs, are needed to justify the
usage of vasopressin and norepinephrine for the treatment of septic shock.
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